A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
August 2, 2018
End Date
December 14, 2023
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
August 2, 2018
End Date
December 14, 2023